Abstract 1851P
Background
We have previously reported on the initial results of the prospective longitudinal PICO-SM study (Lim et al. 2023), highlighting the impact of the COVID-19 pandemic on the lives of patients with colorectal cancer. Herein, we present the psychological impact of the third wave of the pandemic to patients, when the Omicron variant became prevalent (December 2021 to early 2022).
Methods
Patients were invited to participate in cohort II of the PICO-SM study by completing a questionnaire, including screening psychometric tools. Multivariate analysis was performed using logistic regression for binary outcomes: anxiety (GAD-7 score ≥ 5), depression (PHQ-9 score ≥ 10), and poor well-being (WHO-5 < 50); and odds ratios (OR) with 95% confidence interval (CI) were calculated.
Results
In total, 96 participants were included: mean age 64 years, 64% (n = 61) males. 33% (n = 32/96) reported poor well-being (WHO-5 < 50), 27% (n = 26/96) anxiety (GAD-7 ≥ 5), 11% (n = 11/96) depressive symptoms (PHQ-9 ≥ 10) and 3% (n = 3/96) probable post-traumatic stress disorder (PC-PTSD-5 ≥ 4). The results compare with distress levels in the second pandemic wave: 31%, 24%, 15% and 3%, respectively. Multivariate analysis showed that patients who had investigations cancelled (OR 9.22, 95% CI 1.09-77.85; p = 0.041) or felt that the pandemic would affect their mental health (OR 3.82, 95% CI 1.96-7.44; p < 0.001) had increased risk of anxiety. Similarly, concern that the pandemic would affect their cancer treatment (OR 4.59, 95% CI 1.03-20.56; p = 0.046) or would affect their mental health (OR 3.90, 95% CI 1.38-11.03; p = 0.010) were found independent predictors of poor wellbeing.
Conclusions
The psychological distress experienced by patients, particularly anxiety, remained persistently high during the third wave of the COVID-19 pandemic. These updated results align with our initial findings, emphasizing the critical importance of continuing cancer treatment amidst the ongoing humanitarian emergency. It is crucial for healthcare services to prioritize ongoing psychological support for cancer patients, with a particular focus on those who are more vulnerable.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Servier.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2018P - Novel nomogram based on the expression of DLL3 and PD-L1 for predicting the prognosis of small cell lung cancer patients
Presenter: Jun Zhao
Session: Poster session 05
2019P - Analysis of lung immune prognostic index (LIPI) score in a small cell lung cancer carcinoma (SCLC) cohort, supporting its prognostic use and investigating its predictive potential
Presenter: Mónica Esteban García
Session: Poster session 05
2020P - Circulating micro RNAs (cmiRNAs) as treatment outcome predictors in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab plus carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2021P - Cell-free (cf) DNA as predictive biomarker (B) of treatment outcome in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab, carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2022P - ALBA project: Prognostic impact of laterality in small cell lung cancer
Presenter: Lorenza Landi
Session: Poster session 05
2024P - Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: A review on the basis of clinical trials
Presenter: Manuel Dómine
Session: Poster session 05
2025P - Stratified control study of neuroendocrine differentiation and potential clinicopathologic markers
Presenter: Li Liu
Session: Poster session 05
2026P - Small cell lung cancer (SCLC) in the KBP-2020-CPHG cohort and comparison with 2000 and 2010
Presenter: Lionel Falchero
Session: Poster session 05
2027P - Immune checkpoint inhibitors in the treatment of small cell lung cancer: A systematic review and meta-analysis
Presenter: Patsy Lee
Session: Poster session 05